[

bharat biotech

]

Latest from bharat biotech

Bharat Biotech's intranasal vaccine cleared for ‘restricted emergency use’

The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops, a press release said.

An employee of Bharat Biotech speaks on a mobile phone inside a bus (AP Photo)
An employee of Bharat Biotech speaks on a mobile phone inside a bus (AP Photo)
Published on Nov 28, 2022 07:49 PM IST

Nasal vaccines could help control Covid, says WHO

India approved a nasally-administered Covid-19 vaccine for emergency use on Tuesday, developed by Bharat Biotech.

WHO emergencies director Mike Ryan said nasal vaccines generated immune response in the respiratory mucosa in the lungs.(Representative Image)
WHO emergencies director Mike Ryan said nasal vaccines generated immune response in the respiratory mucosa in the lungs.(Representative Image)
Published on Sep 07, 2022 10:08 PM IST

India gets 1st Covid nasal vaccine | Things to know about Bharat Biotech’s jab

Bharat Biotech Covid Vaccine: Bharat Biotech’s needle-free intranasal vaccine will now be used for primary immunization of those aged 18 years and above.

Bharat Biotech Covid Vaccine: Bharat Biotech’s Covid nasal vaccine has been approved.(Representative Image)
Bharat Biotech Covid Vaccine: Bharat Biotech’s Covid nasal vaccine has been approved.(Representative Image)
Published on Sep 06, 2022 07:12 PM IST

Bharat Biotech finishes trials for intranasal Covid vaccine

“Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (two-dose) schedule and a heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid vaccines in India,” Bharat Biotech said in a statement.

Bharat Biotech International Limited, makers of Covaxin vaccine, has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, the company announced on Monday. (Hindustan Times)
Bharat Biotech International Limited, makers of Covaxin vaccine, has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, the company announced on Monday. (Hindustan Times)
Updated on Aug 16, 2022 05:10 AM IST

Bharat Biotech ends intranasal Covid vaccine booster trials, says found safe

Bharat Biotech has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154.

Bharat Biotech’s BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. (File Photo: Hindustan Times)
Bharat Biotech’s BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. (File Photo: Hindustan Times)
Updated on Aug 15, 2022 11:39 PM IST
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Wednesday, November 30, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals